Clinical trials: Neoplasms, Metastatic
HR+/HER2- Locally Advanced, Metastatic Breast Cancer
UK Ibrance Patient Program (IPP) Study
What are the real-world treatment patterns, patients' characteristics, clinical outcomes and healthcare resource utilisation associated with palbociclib treatment in the 3 years following initiation in United Kingdom patients…
- Trial name
- ROIS (NCT03921866)
- Testing
- Palbociclib
- Where
- 8 sites in United Kingdom
- Volunteers
- 191 people
- Sponsor
- Pfizer
Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
This phase I trial is studying the side effects and best dose of alvespimycin hydrochloride in treating patients with metastatic or unresectable solid tumors.
- Conditions
- Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Breast Cancer
- Trial name
- NCT00089362
- Testing
- alvespimycin hydrochloride, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced…
- Conditions
- KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
- Trial name
- KontRASt-01 (NCT04699188)
- Testing
- JDQ443, TNO155, tislelizumab
- Where
- 38 sites in United States, Australia and 14 more
- Volunteers
- 344 people
- Sponsor
- Novartis Pharmaceuticals
Brain Metastases
Perfexion Brain Metastasis
Brain metastases occur in 20% to 40% of all patients with cancer , with an incidence 10 times higher than that of primary malignant brain tumors.
- Trial name
- HF-SRT (NCT00805103)
- Testing
- Hypofractionated stereotactic radiotherapy
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- University Health Network, Toronto
Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocellular Carcinoma
Application of Super-Resolution Ultrasound (SRUS) in Liver Tumor
The macroscopic vascular supply of liver tumors varies considerably according to histological subtype, lesion size, and disease stage.
- Conditions
- Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocellular Carcinoma, Hepatic Hemangioma, Focal Nodular Hyperplasia
- Trial name
- SRUS (NCT07707661)
- Testing
- Perform super-resolution ultrasound imaging on the study population
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer
Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.
This phase II interventional clinical trial aims to evaluate whether combining cetuximab and avelumab, after three cycles of platinum and taxane-based chemotherapy, can improve treatment outcomes for patients with recurrent or…
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
- Trial name
- AVEC-119 (NCT06869473)
- Testing
- Cetuximab/avelumab
- Where
- 8 sites in Italy
- Volunteers
- 67 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Leiomyosarcoma
Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma
This study seeks to determine if addition of trabectedin (T) to combination doxorubicin (D) and olaratumab (O), is feasible and tolerable with antitumor activity in metastatic or recurrent Leiomyosarcomas (LMS) patients who have…
- Trial name
- NCT03437070
- Testing
- Trabectedin, Doxorubicin, Olaratumab
- Sponsor
- University of Miami
Tumors Metastatic to Brain
Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases
Randomized phase III trial to compare the effectiveness of radiation therapy with or without thalidomide in treating patients who have brain metastases. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00033254
- Testing
- radiation therapy, thalidomide, quality-of-life assessment
- Where
- United States
- Volunteers
- 332 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Colon Cancer
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
This pilot clinical trial studies copper Cu 64 anti-carcinoembryonic antigen (CEA) monoclonal antibody M5A positron emission tomography (PET) in diagnosing patients with CEA positive cancer.
- Conditions
- Breast Cancer, Colon Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT02293954
- Testing
- radionuclide imaging, positron emission tomography, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Pancreatic Adenocarcinoma, Colorectal Cancer
Micrometastasis in Gastrointestinal Cancer
Prognostic and predictive value of assessing the patients micrometastasis status in blood and bone marrow when diagnosed GI cancer.
- Trial name
- NCT01919151
- Where
- Norway
- Volunteers
- 500 people
- Sponsor
- Oslo University Hospital
Metastatic Castration Resistant Prostate Cancer Patients
Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program
Toward personalised treatment in early metastatic prostate cancer based on the assessment of biomarkers in cancer tissue samples and circulating tumour cells.
- Trial name
- PETRUS (NCT01786031)
- Testing
- metastasis biopsy
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Metastatic Solid Tumor, Ovarian Cancer
Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 with Olaparib in adult patients with locally advanced or metastatic solid tumors
- Conditions
- Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer, BRCA 1 /2 and / or HRD
- Trial name
- NCT07156253
- Testing
- SYN818 and Olaparib will be administered
- Where
- 2 sites in China
- Volunteers
- 110 people
- Sponsor
- Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT
This is a pilot imaging study for women whose tumors express NIS [Na+I- symporter, sodium iodide symporter]. Eligibility is limited to the presence of strong (3+) and/or plasma membrane staining in > 20% of cells as determined by…
- Conditions
- Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer Metastatic Breast Cancer
- Trial name
- NCT00725946
- Testing
- Iodine-124, PET/CT with Iodine-124
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Stanford University
Malignant Airway Obstruction Secondary to Non-small Cell Lung Cancer
Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients
Assess the safety and feasibility of local oncological drug delivery into the bronchial wall after recanalization of subjects with malignant airway obstruction. Safety and feasibility (technical success) will be assessed.
- Trial name
- BROADWAY (NCT02066103)
- Testing
- Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Mercator MedSystems, Inc.
Non-small Cell Lung Cancer Metastatic
An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC
This study will evaluate the safety, tolerability, pharmacokinetics and efficacy of Oba01 for injection in patients with DR5 positive LA/mNSCLC.
- Trial name
- NCT06083870
- Testing
- Oba01
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Lu Shun
Metastatic Pancreatic Cancer, Metastatic Biliary Tract Cancer
Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients
This is a prospective, randomized, open-label phase 2 study in patients with metastatic PC or BTC refractory or intolerant to at least one line of prior systemic chemotherapy with gemcitabine or platinum-containing regimens to…
- Trial name
- CheckPAC (NCT02866383)
- Testing
- Nivolumab, Ipilimumab, Radiotherapy
- Where
- Denmark
- Volunteers
- 160 people
- Sponsor
- Herlev Hospital
Prostate Cancer, Oligometastatic Disease
High-Risk Metachronous Oligometastatic Prostate Cancer Trial
The purpose of this research study is to compare the effects, good and/or bad, of using the standard of care treatment, hormonal therapy + Stereotactic Ablative Radiation (SABR) to the metastatic lesions, compared to standard of…
- Trial name
- KNIGHTS (NCT06212583)
- Testing
- niraparib/abiraterone acetate, Stereotactic ablative radiation therapy (SABR), Androgen deprivation therapy (ADT)
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- University of Maryland, Baltimore
Metastatic Colorectal Cancer
A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).
The purpose of this study is to collect additional safety and efficacy data during treatment with trifluridine / tipiracil in patients with a pretreated metastatic colorectal cancer (mCRC).
- Trial name
- PRECONNECT (NCT03306394)
- Testing
- Trifluridine/Tipiracil hydrochloride (S95005)
- Where
- 99 sites in Australia, Belgium and 14 more
- Volunteers
- 907 people
- Sponsor
- Institut de Recherches Internationales Servier
Colo-rectal Cancer
The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts
This is an open label, multicenter, randomized study in Chinese patients with RAS and BRAF wild-type mCRC. Participants were randomly assigned to cetuximab + FOLFOX (group A) and cetuximab + modified XELOX[mXELOX] (group B).
- Trial name
- NCT05074966
- Testing
- Experimental: mXELOX plus cetuximab, Active Comparator: FOLFOX plus cetuximab
- Where
- China
- Volunteers
- 314 people
- Sponsor
- Chinese Academy of Medical Sciences
Carcinoid Tumor
A Study of Axitinib in Advanced Carcinoid Tumors
The main purpose of this study is to see whether Axitinib will help prolong the time that the patient's carcinoid tumors remain stable, and to examine their treatment response through testing.
- Trial name
- NCT01435122
- Testing
- Axitinib
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.